Clinical Trial Update: Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating risk-adapted SABR for Stage I non-small cell lung cancer and lung metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasm Metastasis
• Non-small Cell Lung Cancer

Snippet

Sponsor: Institut Català d'Oncologia | Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 2 | Status: UNKNOWN